Vinn, I do agree there are quite a few impressive bios on the...

Vinn, I do agree there are quite a few impressive bios on the MSB website... including Eric Strati (ex Novartis). They also have as head of strategy, the former longstanding cfo of Astra Zeneca ! 

It is good to know that this Company is also heavily focussed on commercialising the science. 

Some commentators are correct in their assessment of the shares technical position... however, I regularly position trade when market conditions are very poor. Put simply, retail investors often panic when the market falls. In these conditions , I like to pick out special situations which should in theory recover quickly on stock specific news flow. I entered MSB too high . I cut my position hard after the LVD results came out, aware that many would misinterpret them ...especially as the management were so slow in explaining their actual relevance. I can now afford to add aggressively at lower levels.

There are not many trading days until January...volumes will be very thin in the fortnight just before Christmas. What are the chances that aGVHD is turned down by the 

FDA after 3 years of successful use in other markets? .. (including for adult as well as paediatric use in Japan !!!) Pure Biotechs have been caught up in a change of risk appetite, triggered by the price earnings rating compression of many excellent growth stocks worldwide. Big Pharmas have mature portfolios and with current low interest rates need to generate returns. They will always seek to put the cash flows to work in this environment by partnering or acquiring to build their product pipeline. Fund managers are so focussed these days on short term performance so it may require industry validation of this technology for them to take notice and jump onboard. MSB has products which meet an unmet clinical need and could soon gain fast track approvals. Just to be clear, I did not invest in MSB until the last few months primarily  because of the balance sheet risks and potential likelihood of a dilutive refinancing.The Tasly deal and other milestone payments relating to Alofisel  has given the Company enough headroom for the time being. If CLBP or CHF have successful P3 trials, ( and I have seen nothing to convince me otherwise) the share price is simply ridiculous compared to other biotechs I have evaluated.